ARROWHEAD PHARMACEUTICALS IN
515 institutions still hold ARROWHEAD PHARMACEUTICALS IN as of Q2 2026. Tracked across SEC 13F-HR filings, with insider and 13D/G activity surfaced alongside.
The two holders who 'control 91%' of Arrowhead Pharmaceuticals' tracked institutional value are, on inspection, two flavors of machinery: Assenagon Asset Management ($16.5 million after a $12.8 million add) is a quasi-passive options-overlay manager, and Y-Intercept ($3.3 million, new this quarter) is a quantitative shop with model-driven turnover. Neither position expresses a view on the RNAi biotech's pipeline. The genuinely discretionary layer of this 22-holder, $21.9 million base is strikingly thin — under $1.5 million in total, moving in five-figure increments: GAMMA Investing added $106,000, LRI Investments $168,000, and two advisors opened starter positions near $200,000 each, against Tema ETFs' $133,000 trim. For a clinical-stage biotech with real binary risk, the honest institutional-ownership read is an absence: fundamental institutions, in this tracked base, are barely present.
Top holders
Sorted by position value. Source: SEC EDGAR 13F-HR filings.